849210-10-2Relevant articles and documents
Decreasing HepG2 Cytotoxicity by Lowering the Lipophilicity of Benzo[d]oxazolephosphinate Ester Utrophin Modulators
Chatzopoulou, Maria,Emer, Enrico,Lecci, Cristina,Rowley, Jessica A.,Casagrande, Anne-Sophie,Moir, Lee,Squire, Sarah E.,Davies, Stephen G.,Harriman, Shawn,Wynne, Graham M.,Wilson, Francis X.,Davies, Kay E.,Russell, Angela J.
supporting information, p. 2421 - 2427 (2020/12/03)
Utrophin modulation is a disease-modifying therapeutic strategy for Duchenne muscular dystrophy that would be applicable to all patient populations. To improve the suboptimal profile of ezutromid, the first-in-class clinical candidate, a second generation
RORGAMMA MODULATORS AND USES THEREOF
-
Page/Page column 41; 59; 60, (2018/08/20)
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF
-
, (2011/04/26)
The present invention relates to epiminocycloalkyl[b]indole derivatives as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, and methods of preparation and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, and schizophrenia. The subject compounds have the structure of formula (I), with the substituents being described herein.
